Nanomedicine and cancer immunotherapy

Yu, Haijun; Geest, Bruno G. De

doi:10.1038/s41401-020-0426-2

Cited by 38 publications

(21 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The more faithful recapitulation of the in vivo TME through the inclusion of immune system components will support the accurate prediction of clinical responses to a novel therapeutic [151] . Moreover, the immune system itself represents a crucial target for rationally designed nanomedicines, which can either activate the immune system against the tumor (e.g., nanovaccines) or eliminate those immune cells that support tumor growth and metastasis [152] , [153] , [154] .…”

Section: Pre-clinical Breast Cancer Animal Modelsmentioning

confidence: 99%

The past, present, and future of breast cancer models for nanomedicine development

Boix-Montesinos

Soriano-Teruel

Armiñán

et al. 2021

Advanced Drug Delivery Reviews

View full text Add to dashboard Cite

show abstract

Section: Pre-clinical Breast Cancer Animal Modelsmentioning

confidence: 99%

The past, present, and future of breast cancer models for nanomedicine development

Boix-Montesinos

Soriano-Teruel

Armiñán

et al. 2021

Advanced Drug Delivery Reviews

View full text Add to dashboard Cite

show abstract

“…Therefore, to overcome these limitations the design of nanoparticles must focus upon its characteristics such as surface morphology and size, its uptake or internalization process, release mechanism for better biodistribution, biocompatibility and pharmacokinetics [73][74][75]. Further, doing so will reprogram or introduce functional modulation in antitumor immune response generated at TME [76,77] (Figure 1).…”

Section: Nano-immunotherapeutic For Cancer Treatmentmentioning

confidence: 99%

Nano-immunotherapeutics: targeting approach as strategic regulation at tumor microenvironment for cancer treatment

Singh

Yadav

Niveria

et al. 2022

Exploration of Medicine

View full text Add to dashboard Cite

Cancer is the leading cause of mortality worldwide, which necessitates our consideration related to novel treatment approach. Tumor cells at the tumor microenvironment (TME), regulate a plethora of key mechanistic signaling pathways that obstruct antitumor immune responses by immune suppression, immune resistance or acquired immune tolerance. The present therapeutic regimes are provided independently or in combination, or as immunotherapies for cancer immune targeting. Immunotherapy has altered the arena of oncology and patient care. By using the host immune system, the immunostimulatory molecules can exert a robust, personalized response against the patient’s own tumors. Alternatively, tumors may exploit these strategies to escape immune recognition, and accordingly, such mechanisms represent chances for immunotherapy intervention. Nonetheless, despite promising outcomes from immunotherapies in recurrent and metastatic cancers, immune-therapeutics in clinics has been limited owing to unpredictability in the produced immune response and reported instances of immune-related adverse effects. The unrealized potential of immunotherapies in cancer management maybe due to the obstacles such as heterogeneous nature, multiple targets, patients’ immune response, specificity for cancer or variability in response generation in toxicity levels, delivery and cost related to therapeutics etc. Further revolutionary trends related to immunotherapies are noticeable with slower progress for cancer management. Recent advances in nanomedicine strategize to ameliorate the lacuna of immunotherapy as it relies on the inherent biophysical characteristics of nanocarriers: size, shape, surface charge and multifunctionality and exploiting them as first line therapy for delivery of biomolecules, single checkpoint inhibitors and for imaging of TME. Therefore, nano-assisted immunotherapies can boost the immunotherapeutic approach, overcoming factors that are with imminent potential risks related to it, thereby significantly improving the survival rate associated with it in cancer patients. Nanotechnology is anticipated to overcome the confines of existing cancer immunotherapy and to successfully combine various cancer treatment modes.

show abstract

“…Nanotechnology can simultaneously deliver various immunological reagents to the desired target site (tumor or lymph node). The ultimate application of nanomedicine is to reprogram or to regulate immune responses by accurately targeting biological pathways ( Yu and De Geest, 2020 ). Hence, the emergence of nanotechnology provides a variety of materials and targeted properties to overcome many difficulties in immunotherapy.…”

Section: The Emergence Of Nanotechnology For Cancer Immunotherapymentioning

confidence: 99%

The Application of and Strategy for Gold Nanoparticles in Cancer Immunotherapy

Liu

Zhang

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

Immunotherapy of malignant tumor is a verified and crucial anti-tumor strategy to help patients with cancer for prolonging prognostic survival. It is a novel anticancer tactics that activates the immune system to discern and damage cancer cells, thereby prevent them from proliferating. However, immunotherapy still faces many challenges in view of clinical efficacy and safety issues. Various nanomaterials, especially gold nanoparticles (AuNPs), have been developed not only for anticancer treatment but also for delivering antitumor drugs or combining other treatment strategies. Recently, some studies have focused on AuNPs for enhancing cancer immunotherapy. In this review, we summarized how AuNPs applicated as immune agents, drug carriers or combinations with other immunotherapies for anticancer treatment. AuNPs can not only act as immune regulators but also deliver immune drugs for cancer. Therefore, AuNPs are candidates for enhancing the efficiency and safety of cancer immunotherapy.

show abstract

Nanomedicine and cancer immunotherapy

Cited by 38 publications

References 11 publications

The past, present, and future of breast cancer models for nanomedicine development

The past, present, and future of breast cancer models for nanomedicine development

Nano-immunotherapeutics: targeting approach as strategic regulation at tumor microenvironment for cancer treatment

The Application of and Strategy for Gold Nanoparticles in Cancer Immunotherapy

Contact Info

Product

Resources

About